Results 131 to 140 of about 29,030 (239)

Unilateral optic neuritis and thinning of retinal layers in the affected and unaffected eyes

Acta Ophthalmologica, Volume 104, Issue 1, Page e84-e94, February 2026.
Abstract Purpose Multiple sclerosis (MS)‐related optic neuritis (ON) causes thinning of inner retinal layers. It remains unclear whether unilateral MSON also affects the unaffected contralateral eye. The purpose of this study was to compare macular retinal layer thicknesses in MS eyes with unilateral optic neuritis (MSON), their unaffected ...
Sanna Leinonen, Hanna‐Mari Mäkelä, Chi Li, Leopold Schmetterer, Jacqueline Chua   +4 more
wiley   +1 more source

Interferon beta 1b following natalizumab discontinuation: one year, randomized, prospective, pilot trial [PDF]

, 2013
Background: Natalizumab (NTZ) discontinuation leads to multiple sclerosis reactivation. The objective of this study is to compare disease activity in MS patients who continued on NTZ treatment to those who were switched to subcutaneous interferon 1b ...
Cotton, François, Gobbi, Claudio, Guttmann, Charles R G, Leppert, David, Meier, Dominik S, Sintzel, Martina, Zecca, Chiara   +6 more
core   +4 more sources

Targeting Overexpressed IDO in Stromal Cells as a Potential Therapeutic Strategy in Multiple Myeloma

Cancer Science, Volume 117, Issue 2, Page 325-334, February 2026.
IDO expression in stromal cells was upregulated by MM cells via the JAK–STAT1–NF‐κB–IRF1 signaling pathway. JAK inhibitor abolished IDO and IRF1 upregulation. ABSTRACT Stromal cells are an essential component of the tumor microenvironment (TME) in multiple myeloma (MM). Indoleamine 2,3‐dioxygenase 1 (IDO), an enzyme that metabolizes tryptophan (Trp) to
Toru Ebina, Masaki Ri, Yoshiaki Marumo, Tomoyuki Nakamura, Hirokazu Sasaki, Yoshiko Oshima, Takahiro Nakashima, Shinya Hagiwara, Arisa Asano, Shiori Kinoshita, Tomotaka Suzuki, Tomoko Narita, Ayako Masaki, Takaomi Sanda, Kazufumi Yamagata, Kohmei Kubo, Hirokazu Komatsu, Hirotake Sakuraba, Shinsuke Iida   +18 more
wiley   +1 more source

Factors that Lead to the Immunotherapy Gap in Multiple Sclerosis Testing [PDF]

, 2013
Multiple sclerosis is a disease that affects the central nervous system. Most doctors and scientists believe that it is an autoimmune disease.
Solai, Karthika
core   +1 more source

Autologous hematopoietic cell transplantation in multiple sclerosis. [PDF]

, 2016
INTRODUCTION: Autologous haematopoietic cell transplantation (AHCT) is an evolving treatment avenue in multiple sclerosis (MS), which may be highly effective in controlling disease activity and improving disability.
Basil Sharrack, Burt RK, John A. Snowden, La Mantia L, Martinelli Boneschi F, Simon M. Bell, van Gelder M   +6 more
core   +1 more source

Patient Preference for Subcutaneous Versus Intravenous Administration with Every-6-Week Natalizumab (Tysabri®) Dosing: NOVA Phase IIIb Extension Study (Part 2)

Neurology and Therapy
Introduction Following NOVA (part 1) and the approval of the subcutaneous (SC) route of administration of natalizumab by the European Medicines Agency, an extension phase of the NOVA phase IIIb study (part 2) was initiated to collect patient preference ...
Heinz Wiendl, John Foley, Gilles Defer, Lana Zhovtis Ryerson, Jeffrey A. Cohen, Douglas L. Arnold, Helmut Butzkueven, Gary R. Cutter, Gavin Giovannoni, Joep Killestein, Rose Domingo-Horne, Marie Toukam, Aimie Nunn, Amir-Hadi Maghzi, Robert Kuhelj, Tyler Lasky   +15 more
doaj   +1 more source

Spanish consensus on the use of natalizumab (Tysabri®)-2013

Neurología (English Edition), 2015
Introduction: Natalizumab treatment has been shown to be very efficacious in clinical trials and very effective in clinical practice in patients with relapsing-remitting multiple sclerosis, by reducing relapses, slowing disease progression, and improving
O. Fernández, J.A. García-Merino, R. Arroyo, J.C. Álvarez-Cermeño, G. Izquierdo, A. Saiz, J. Olascoaga, A. Rodríguez-Antigüedad, J.M. Prieto, C. Oreja-Guevara, M.A. Hernández, E. Moral, J. Meca, X. Montalbán   +13 more
doaj   +1 more source

EFFICIENT PROPAGATION OF ARCHETYPE JC POLYOMAVIRUS IN COS-7 CELLS: EVALUATION OF REARRANGEMENTS WITHIN NCCR STRUCTURAL ORGANIZATION DURING TRANSFECTION. [PDF]

, 2017
John Cunningham virus (JCPyV) is an ubiqui-tous human pathogen that causes disease in immunocom-promised patients. The JCPyV genome is composed of an early region and a late region, which are physically sepa-rated by the ...
Anzivino, Elena, Bellizzi, Anna, Palamara, ANNA TERESA, Pietropaolo, Valeria Antonietta, Prezioso, Carla, Rodio, DONATELLA MARIA, Scribano, D, Trancassini, Maria   +7 more
core   +1 more source

Nearly one-half of Brazilian patients with multiple sclerosis using natalizumab are DNA-JC virus positive

Arquivos de Neuro-Psiquiatria, 2013
Objective Natalizumab is a new and efficient treatment for multiple sclerosis (MS). The risk of developing progressive multifocal leukoencephalopathy (PML) during the use of this drug has created the need for better comprehension of JC virus (JCV ...
Yara Dadalti Fragoso, Maria Fernanda Mendes, Walter Oleschko Arruda, Jefferson Becker, Joseph Bruno Bidin Brooks, Margarete de Jesus Carvalho, Elizabeth Regina Comini-Frota, Renan Barros Domingues, Maria Lucia Brito Ferreira, Alessandro Finkelsztejn, Paulo Diniz da Gama, Sidney Gomes, Marcus Vinicius Magno Goncalves, Damacio Ramon Kaimen-Maciel, Rogerio de Rizo Morales, Andre Muniz, Heloisa Helena Ruocco, Pedro Rippel Salgado, Livia Brito Bezerra de Albuquerque, Rodrigo Assad Diniz da Gama, Sergio Georgeto, Josiane Lopes, Celso Luis Silva Oliveira, Francisco Tomaz Meneses Oliveira, Juliana Safanelli, Patricia Correia de Oliveira Saldanha, Massaco Satomi   +26 more
doaj   +1 more source

A Representative Survey of M.S. Patients on Attitudes toward the Benefits and Risks of Drug Therapy [PDF]

Background: Although M.S. patients face significant trade-offs between risks and benefits of drug therapy, little is known of their attitudes toward these risks and benefits.
Calfee, John E.
core   +1 more source